[{"Abstract":"Glutathione S-transferase pi 1 (<i>GSTP1<\/i>) is expressed at low levels in normal prostate luminal cells and becomes induced in most proliferative inflammatory atrophy lesions (PIA). <i>GSTP1<\/i> becomes silenced in prostatic intraepithelial neoplasia (PIN) and prostate adenocarcinoma (CaP) via CpG island promoter hypermethylation. However, the specific methylation patterns in CaP and its precursors have not been investigated. We used bisulfite genomic sequencing to examine methylation of 39 CpG sites in the <i>GSTP1 <\/i>promoter. Radical prostatectomy specimens were selected from 32 subjects that underwent treatment for CaP. Serial sections were subjected to laser capture microdissection for enrichment of epithelial cells from benign, PIA, PIN, and CaP regions. Isolated DNA was bisulfite converted. Sequences corresponding to the <i>GSTP1 <\/i>promoter CpG island were amplified with nested PCR, and PCR products were cloned. 10 independent clones were sequenced and analyzed with a Java program, DNAMethylMap, to determine the methylation pattern of 39 CpG sites of the <i>GSTP1 <\/i>promoter in each lesion. The extent of methylation on an individual allele was classified as negative (&#60;10% CpGs), mild (10-25%), moderate (25-50%), or high (&#62;50%). 212 clones from 24 normal epithelium regions, 327 clones from 37 PIA regions, 167 clones from 18 PIN regions, and 202 clones from 23 CaP regions were sequenced, totaling 34863 CpG sites. Normal and PIA lesions were mostly unmethylated with 0.52% and 1.3% of total CpG sites methylated, respectively. Methylated PIA lesions were adjacent to CaP or PIN regions significantly more often than unmethylated PIA lesions (&#967;2, p = 0.012). PIN and CaP lesions had greater methylation with 24% and 51% of total CpG sites methylated, respectively. PIN lesions generally showed partial methylation with 28.7% of alleles in PIN having mild\/moderate methylation density compared to 5.5% in PIA and 11% in CaP. PIA and PIN lesions were enriched for methylation changes at 6 CpG sites that aligned with AP1 and SP1 binding sites. Among 16 PIN and CaP lesions with an overall intermediate level of methylation, 5 of the lesions had clones that clustered into either fully methylated or unmethylated. One patient with 3 CaP lesions displayed significant heterogeneity in methylation patterns: full, moderate, or no methylation across all clones in a given lesion. The results demonstrate that methylation density in the <i>GSTP1 <\/i>CpG island from PIN was intermediate between normal prostate epithelium\/PIA and CaP lesions. The observed methylation in PIA and PIN was enriched at binding sites of key transcription factors, AP1 and SP1. The results are consistent with gradual spreading of DNA methylation centered at the transcription factor binding sites in the putative precursor lesions, with subsequent spreading of methylation across the entire CpG island in transition to CaP.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/c12dc148-3f58-4812-bba9-97b2be779840\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"GSTP1,DNA methylation,Promoter methylation,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17255"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Harshath Gupta<\/i><\/u><\/presenter>, <presenter><i>Hitoshi Inoue<\/i><\/presenter>, <presenter><i>Yasutomo Nakai<\/i><\/presenter>, <presenter><i>Masashi Nakayama<\/i><\/presenter>, <presenter><i>William G. Nelson<\/i><\/presenter>, <presenter><i>Angelo M. De Marzo<\/i><\/presenter>, <presenter><i>Srinivasan Yegnasubramanian<\/i><\/presenter>. Johns Hopkins University School of Medicine, Baltimore, MD, Ikeda Municipal Hospital, Osaka, Japan, Osaka International Cancer Institute, Osaka, Japan","CSlideId":"","ControlKey":"62b57795-e4bb-4b4a-b619-1b7c73ca8a53","ControlNumber":"1706","DisclosureBlock":"&nbsp;<b>H. Gupta, <\/b> None..<br><b>H. Inoue, <\/b> None..<br><b>Y. Nakai, <\/b> None..<br><b>M. Nakayama, <\/b> None.&nbsp;<br><b>W. G. Nelson, <\/b> <br><b>Cepheid LLC<\/b> Independent Contractor, No. <br><b>A. M. De Marzo, <\/b> <br><b>Cepheid LLC.<\/b> Independent Contractor, No. <br><b>S. Yegnasubramanian, <\/b> <br><b>Cepheid LLC.<\/b> Independent Contractor, Grant\/Contract, No.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17255","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/c12dc148-3f58-4812-bba9-97b2be779840\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3734","PresenterBiography":null,"PresenterDisplayName":"Harshath Gupta, BA","PresenterKey":"4f46de42-8d1d-4d97-996a-43c305af2ae8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3734. Progressive spreading of CpG methylation in the CpG island of Glutathione S-Transferase pi 1 (GSTP1) alleles across transitions from precursor to invasive prostate cancer","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Progressive spreading of CpG methylation in the CpG island of Glutathione S-Transferase pi 1 (GSTP1) alleles across transitions from precursor to invasive prostate cancer","Topics":null,"cSlideId":""},{"Abstract":"Human papillomavirus (HPV) causes approximately 80% of head and neck squamous cell carcinoma (HNSCC) in the oropharynx, and its incidence is now higher than uterine cervical cancer in the US. The CDC estimates that this common sexually transmitted disease accounts for nearly 13,000 HPV+ HNSCC patients per year in the United States. Despite having a higher cure rate than HPV- HNSCC, the recurrence rate is approximately 30%. These patients have few therapeutic options since resistance to treatment arises from all known therapeutic modalities. Initial therapy for HPV+ HNSCC is aggressive and often results in negative lifelong side effects. The substantial recurrence rate and high morbidity of primary therapy suggest the need for new treatments. Global genome hypermethylation in HPV+ HNSCC, compared to HPV-, prompted our lab to explore demethylation as a therapeutic option. 5-azacytidine (5-aza) and 5-aza-2&#8242;-deoxycytidine (decitabine) are synthetic cytidine analogs that cause DNA demethylation by trapping methyltransferases to chromatin. These demethylating agents are FDA approved for the treatment of myelodysplasia and acute myeloid leukemia. Recently, we found that HPV+ HNSCC cells are more sensitive than HPV- cells to 5-aza, that low doses of 5-aza delayed HPV+ xenograft tumor growth, and that HPV+ tumor samples from patients treated with 5-aza in a window trial had increased apoptosis. We also observed a marked downregulation of HPV gene expression after 5-aza. Decreased HPV E6 expression, followed by reactivation of tumor suppressor p53, induced p53-dependent apoptosis in HPV+ HNSCC. Thus, decreased expression of HPV genes is an important component of 5-aza-associated toxicity toward HPV+ HNSCC; therefore, we further explored mechanisms through which demethylation negatively regulates the expression of HPV genes. First, we determined that 5-aza regulates transcription of HPV genes, but not the stability of HPV transcripts. Second, we found that transcriptional regulation of HPV genes after 5-aza depends on the proto-oncogene JunB, a component of the transcription factor Activator Protein 1 (AP-1). Moreover, our experiments revealed that clonogenic survival of HPV+ head and neck cancer cells is dependent on JunB expression. In summary, our study provides an improved mechanistic understanding of the regulation of HPV gene transcription in HNSCC and identifies a novel HPV+ HNSCC dependency on JunB, potentially providing a basis for a new rational targeted therapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/28605d0c-72de-49c1-af70-80952e01cfce\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Head and neck squamous cell carcinoma,Human papillomavirus (HPV),AP-1,Transcriptional regulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17256"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Hina Rehmani<\/i><\/u><\/presenter>, <presenter><i>Natalia Isaeva<\/i><\/presenter>, <presenter><i>Wendell G. Yarbrough<\/i><\/presenter>. University of North Carolina at Chapel Hill, Chapel Hill, NC","CSlideId":"","ControlKey":"0bba4e60-be6a-4395-a065-22785eca0b04","ControlNumber":"2405","DisclosureBlock":"&nbsp;<b>H. Rehmani, <\/b> None..<br><b>N. Isaeva, <\/b> None..<br><b>W. G. Yarbrough, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17256","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/28605d0c-72de-49c1-af70-80952e01cfce\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3735","PresenterBiography":null,"PresenterDisplayName":"Hina Rehmani, BS;PhD","PresenterKey":"c7a4c251-3aac-418c-b768-347c8b632e35","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3735. Regulation of HPV gene expression by 5-azacytidine treatment in head and neck cancer","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Regulation of HPV gene expression by 5-azacytidine treatment in head and neck cancer","Topics":null,"cSlideId":""},{"Abstract":"<b>Purpose:<\/b> SETD2 aberrancy, as the main reason of depleted levels of H3K36me3, plays an important role in diverse forms of cancer and is most notably in clear cell renal cell carcinoma (ccRCC). Altered chromatin modelers related to impaired H3K36me3 occupancy are linked to renal cancer aggressiveness and metastasis, where the latter dramatically drops the relative 5-year survival rate of ccRCC from 91% to 11%. Developing novel treatment targeting H3K36me3-compromised cancer cell is urgently needed for diagnostic and treatment purposes.<br \/><b>Methods: <\/b>Phenotypic and animal experiments were conducted to test the sensitivity of kidney cancer cells with impaired H3K36me3 to hypomethylating agent (HMA), PARP inhibitor (PARPi), and HMA + PARPi combination treatments. Comet assay, flow cytometry, western blot and bioinformatic analysis were performed to explore the mechanism beneath.<br \/><b>Results:<\/b> Combination treatment of 5-Aza-CdR (DAC) and Talazoparib (PARPi) generate more cytotoxicity in SETD2-altered ccRCC cell lines than in SETD2-intact cell lines, including inhibited cell growth, incomplete colony formation, more apoptosis, increased DNA damage and impaired DNA damage repair. The up-regulation of STING and transposable element (TE), as well as the loss of chromatin stability, were more remarkable in SETD2-altered ccRCC cell lines when treated with DAC + PARPi.<br \/><b>Conclusion:<\/b> Combination treatment of DAC and Talazoparib showed greater synergistic anti-tumor effect in SETD2 aberrant than in SETD2 wild-type ccRCC cells, making it a potential treatment strategy for H3K36me3-compromised cancers. Further pre-clinical studies should be conducted to make a precise medicine-based approach.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/f179c2e9-696c-437f-b731-3450e7571781\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Renal cell carcinoma,SETD2,DNA hypomethylating agent,PARP inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17259"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Xinyi Zhou<\/i><\/u><\/presenter>, <presenter><i>Guanghou Fu<\/i><\/presenter>, <presenter><i>Hong-Tao Li<\/i><\/presenter>, <presenter><i>Hemant Gujar<\/i><\/presenter>, <presenter><i>Daniel J. Weisenberger<\/i><\/presenter>, <presenter><i>David I. Quinn<\/i><\/presenter>, <presenter><i>Bo Han<\/i><\/presenter>, <presenter><i>Gangning Liang<\/i><\/presenter>. Keck School of Medicine, University of Southern California, Los Angeles, CA, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Keck School of Medicine, University of Southern California, Los Angeles, CA, Keck School of Medicine, University of Southern California, Los Angeles, CA, Keck School of Medicine, University of Southern California, Los Angeles, CA, Keck School of Medicine, University of Southern California, Los Angeles, CA","CSlideId":"","ControlKey":"fad90007-7e75-4b37-88ac-4f574c2e5102","ControlNumber":"909","DisclosureBlock":"&nbsp;<b>X. Zhou, <\/b> None..<br><b>G. Fu, <\/b> None..<br><b>H. Li, <\/b> None..<br><b>H. Gujar, <\/b> None..<br><b>D. J. Weisenberger, <\/b> None..<br><b>D. I. Quinn, <\/b> None..<br><b>B. Han, <\/b> None..<br><b>G. Liang, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17259","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/f179c2e9-696c-437f-b731-3450e7571781\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3736","PresenterBiography":null,"PresenterDisplayName":"Xinyi Zhou, BS","PresenterKey":"538e6b0b-93b6-4efe-96af-c37bcce66db0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3736. SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Infants and young children (&#62; 3 yrs.) harboring ETO2-GLIS2 have the worst outcomes amongst all pediatric acute myeloid leukemia (AML) subtypes, with poor responses to induction therapy, high incidence of relapse, and dismal 5-year survival rates. Previous studies demonstrated that the ETO2-GLIS2 fusion leads to imbalance in the expression of ETS-related transcription factor <i>ERG<\/i> and <i>GATA1<\/i> with neo-super enhancer (SE) activities in a single oncogenic hit (Thirant et al. 2017). ERG was found to co-localize with ETO2-GLIS2 fusion at 90% (372\/419) of H3K27ac marked SE-regions and was strongly upregulated (9.44-fold). Herein, we aimed to investigate cooperativity of DNA methylation and chromatin marks on ERG overexpression in this AML subtype. We analyzed transcriptomic data from pediatric ETO2-GLIS2 AML patients (n=40) from dbGAP (phs000465.v19. p8) in comparison to normal bone marrow (NBM) (n=71) samples, confirming upregulation (median log FC: 2.4-fold) in <i>ERG<\/i> expression in the ETO2-GLIS2 subgroup compared to NBM. Next, we performed an unbiased genome-wide methylation array using Infinium MethylationEPIC 850K-arrays (Illumina). Differences in mean methylation (&#946;-value) at individual CpG sites between NBM and AML samples were considered significant at differences greater than &#177;10%. We observed reduced methylation at 72% (5\/7) CpGs at the <i>ERG<\/i>-promoter (1500bp upstream of transcription start site) in ETO2-GLIS2 subgroup compared to NBM. Overall median methylation across the promoter was reduced by 12% in the AML subgroup. In comparison, 22 differentially methylated CpGs were observed in the body, of which methylation increased at 68% (15\/22) of the CpGs, with median methylation similarly increased by 15% in the AML patients. This represents a classic example of methylation-expression relation, having a promoter demethylation and body-hypermethylation, linked to upregulation of the gene-expression. Next, we investigated the overlaps between CpGs and the distribution of DNAse clusters and H3K27ac marks based on ENCODE data on myeloid leukemia cell line K562. We observed frequent overlaps between demethylated CpGs and DNAse clusters, while H3K27ac broad peaks were coincident with both demethylated CpGs at promoter or hypermethylated CpGs at body. Based on our findings, we thus conclude that DNA-methylation both at the <i>ERG<\/i> promoter and body is tightly linked to the overlapping chromatin marks of the gene. DNA-methylation might aid in opening of adjacent chromatin on <i>ERG<\/i> to possibly facilitate SE enrichment and over-expression the gene. Future studies will investigate targeted alterations of DNA-methylation on the gene to test the impact on <i>ERG<\/i> expression and leukemic growth.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/e70d384a-9ad8-4de5-b092-dd605bfcd5a4\/@u03B8ZJP\/vod?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"DNA methylation,Acute myeloid leukemia,Pediatric cancers,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17260"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Samrat Roy Choudhury<\/i><\/u><\/presenter>, <presenter><i>Jordan T. Bird<\/i><\/presenter>, <presenter><i>Stephanie Byrum<\/i><\/presenter>, <presenter><i>Jason E. Farrar<\/i><\/presenter>. Arkansas Children's Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, University of Arkansas for Medical Sciences, Little Rock, AR","CSlideId":"","ControlKey":"45e5f036-ac3b-4d24-8ec8-5221c02c2754","ControlNumber":"5109","DisclosureBlock":"&nbsp;<b>S. Roy Choudhury, <\/b> None..<br><b>J. T. Bird, <\/b> None..<br><b>S. Byrum, <\/b> None..<br><b>J. E. Farrar, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17260","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/e70d384a-9ad8-4de5-b092-dd605bfcd5a4\/@u03B8ZJP\/vod?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3737","PresenterBiography":null,"PresenterDisplayName":"Samrat Roy Choudhury, PhD","PresenterKey":"dd4ef822-0795-469b-b38d-8a4ea9430309","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3737. DNA-methylation is tightly linked with super-enhancer marks to upregulate ERG in ETO2-GLIS2 positive leukemia","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"DNA-methylation is tightly linked with super-enhancer marks to upregulate ERG in ETO2-GLIS2 positive leukemia","Topics":null,"cSlideId":""},{"Abstract":"Background and aims: The early detection of colorectal cancer (CRC) recurrence and the monitoring of therapeutic response are crucial steps in the determination and modification of treatment strategies. The currently used gold standard tumor markers such as CEA and CA 19-9 and the different imaging techniques have several limitations in many cases. Therefore, we aimed to establish a liquid biopsy-based approach for tracking tumor dynamics in post-operative non-metastatic (n=32) and metastatic (n=23) CRC patients.<br \/>Methods: Blood samples were collected from each patient before and during chemotherapy, and finally, patients were classified according to disease outcome. Longitudinal investigations of the total amount, global and local (SFRP2 and SDC2 genes) DNA methylation pattern of cell-free DNA (cfDNA) fraction were performed. The plasma concentration of homocysteine was also determined, as it is one of the main components of the DNA methylation process, and its level defines the methylation potential. We examined how the parameters mentioned above were affected depending on the different therapy responses.<br \/>Results: The average cfDNA amount was significantly higher (p&#60;0.05) in patients with recurrent cancer (30.4&#177;17.6ng) and progressive disease (PD) (44.3&#177;34.5ng) than individuals who achieved remission (REM) (13.2&#177;10.0ng). More than 10% elevation of cfDNA from first to last sample collection was detected in 92% of PD patients, while reduced cfDNA concentration was observed in 67% of the non-metastatic CRC patients with REM. An effective differentiation was detected between patients achieving remission and showing tumor progression based on cfDNA level with 94% sensitivity and 81% specificity. The average global cfDNA methylation was determined by bisulfite pyrosequencing analysis of long interspersed nuclear element-1 (LINE-1), and it was significantly lower (p&#60;0.05) in the PD group compared to people with remission (71.0&#177;6.7% vs. 78.9&#177;2.0%). Methylation level changes between the study beginning and end indicated a decline (75.5&#177;3.4% vs. 68.2&#177;8.4%) in PD; in contrast, we found a reverse change in remission. The mean relative change of homocysteine concentration revealed an opposite trend with the global DNA methylation suggesting a linkage between these parameters, as it showed an increase (+12.5%) in the case of PD and a decrease (-15.8%) in patients with REM. Regarding local DNA methylation, SFRP2 and SDC2 genes revealed higher promoter hypermethylation in the PD set compared to patients with remission.<br \/>Conclusion: Our study offers the possibility to monitor the therapeutic response during chemotherapy with a minimally-invasive blood-based method that combines the analysis of cfDNA, its global and local DNA methylation pattern, and homocysteine level.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/c57c656b-261e-44e0-bc41-46dbe67a2ea0\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Colorectal cancer,Liquid biopsies,Methylation,Cell-free DNA,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17261"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Barbara Kinga Bartak<\/i><\/u><\/presenter>, <presenter><i>Tamás Fodor<\/i><\/presenter>, <presenter><i>Alexandra Kalmár<\/i><\/presenter>, <presenter><i>Zsófia Brigitta Nagy<\/i><\/presenter>, <presenter><i>Sára Zsigrai<\/i><\/presenter>, <presenter><i>Krisztina Andrea Szigeti<\/i><\/presenter>, <presenter><i>William Kothalawala<\/i><\/presenter>, <presenter><i>Gábor Valcz<\/i><\/presenter>, <presenter><i>Péter Igaz<\/i><\/presenter>, <presenter><i>István Takács<\/i><\/presenter>, <presenter><i>Magdolna Dank<\/i><\/presenter>, <presenter><i>Béla Molnár<\/i><\/presenter>. Semmelweis University, Budapest, Hungary, Hungarian Academy of Sciences, Budapest, Hungary, Semmelweis University, Budapest, Hungary","CSlideId":"","ControlKey":"34c93b3f-a995-4007-a5bb-5bff8d144ac3","ControlNumber":"3062","DisclosureBlock":"&nbsp;<b>B. Bartak, <\/b> None..<br><b>T. Fodor, <\/b> None..<br><b>A. Kalmár, <\/b> None..<br><b>Z. Nagy, <\/b> None..<br><b>S. Zsigrai, <\/b> None..<br><b>K. Szigeti, <\/b> None..<br><b>W. Kothalawala, <\/b> None..<br><b>G. Valcz, <\/b> None..<br><b>P. Igaz, <\/b> None..<br><b>I. Takács, <\/b> None..<br><b>M. Dank, <\/b> None..<br><b>B. Molnár, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17261","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/c57c656b-261e-44e0-bc41-46dbe67a2ea0\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3738","PresenterBiography":null,"PresenterDisplayName":"Barbara Kinga Bartak, PhD","PresenterKey":"c75fca66-e371-49d9-8889-a0531ce1cfef","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3738. Monitoring chemotherapy response status of colorectal cancer patients using liquid biopsy samples","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Monitoring chemotherapy response status of colorectal cancer patients using liquid biopsy samples","Topics":null,"cSlideId":""},{"Abstract":"The study of DNA methylation from cell-free DNA (cfDNA) and DNA extracted from formalin fixed paraffin embedded (FFPE) tissues are notoriously difficult. The use of these DNA inputs is becoming increasingly important in the field of cancer diagnostics. The cytosine modifications, 5-methylcytosines (5mC) and 5-hydroxymethylcytosines (5hmC), are key epigenetic factors that play an important role in cellular processes and their mis-regulation results in diseased states like cancer. Advances in the study of these epigenetic factors in combination with improvements in sample preparation have enabled cancer biomarker identification based on methylation profiling.<br \/>The historical gold standard for detecting cytosine methylation has been bisulfite sequencing. This method uses chemical conversion of cytosines into uracils and has been used for both targeted and whole genome methylation analysis. However, bisulfite conversion leads to DNA damage which results in shorter DNA insert sizes as well as biases in the data. It is challenging to make bisulfite libraries from cfDNA and FFPE DNA as typically the DNA is of low quantity and quality.<br \/>We developed an enzyme-based methylation detection technology (EM-seq) to address the flaws inherent to bisulfite sequencing. This method, primarily due to the intact nature of DNA after conversion, results in better quality libraries with longer insert sizes, lower duplication rates and minimal GC bias. EM-seq libraries prepared from cfDNA and lung FFPE DNA had longer inserts, lower duplication rates, higher percentages of mapped reads and less GC bias compared to bisulfite libraries. EM-seq libraries also identified a higher number of CpGs with even coverage facilitating accurate methylation calling. EM-seq&#8217;s superior sequencing metrics establish it as a standard method for robust methylation profiling, particularly for these types of challenging DNA samples.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/4fb52254-309c-4f17-90b3-0e51372bcdea\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Epigenetics,Methylation,cfDNA,EM-seq,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17263"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Louise Williams<\/i><\/u><\/presenter>. New England BioLabs, Ipswich, MA","CSlideId":"","ControlKey":"58567132-830e-43bf-85bb-73af2503517b","ControlNumber":"3646","DisclosureBlock":"<b>&nbsp;L. Williams, <\/b> <br><b>New England BioLabs<\/b> Employment, Yes.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17263","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/4fb52254-309c-4f17-90b3-0e51372bcdea\/@u03B8ZJP\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3739","PresenterBiography":null,"PresenterDisplayName":"Louise Williams, PhD","PresenterKey":"6568ebff-c31d-4d36-829c-d9b7e9c1b243","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3739. EM-seq permits accurate and precise methylome analysis of cfDNA and FFPE DNA","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"EM-seq permits accurate and precise methylome analysis of cfDNA and FFPE DNA","Topics":null,"cSlideId":""},{"Abstract":"The main function of the single-carbon metabolic cycle is maintaining nucleotide pool and DNA methylation which is highly influenced by the chemotherapy protocols. This study aimed to evaluate the ultrashort effect of reduced folate combined anticancer treatment on peripheral blood parameters of colorectal cancer (CRC) patients. Post-operative CRC patients were treated with chemotherapy using the combination of oxaliplatin, 5-FU, leucovorin, and capecitabine. Blood samples were taken until the beginning of the treatment and immediately after the therapy. Plasma fractions were separated and the levels of S-adenosylmethionine (SAM), S-adenosyl homocysteine (SAH) and the simultaneous quantification of nucleotides (adenine, cytosine, thymine, guanine and uracil) were detected by HPLC-MS\/MS. Homocysteine (HCY) was also determined from plasma specimens. Cell-free DNA (cfDNA) was isolated from plasma and DNA methylation was analyzed by LINE-1 bisulfite pyrosequencing. Moreover, LINE-1 methylation statuses were also examined from PBMC cells that were separated from whole blood by a density gradient centrifugation. In each patient, the HCY level of plasma was decreased by an average of 17% after oxaliplatin treatment with the combination of capecitabine (XELOX) and also with 5-FU + leucovorin (FOLFOX) agents. Our study also confirmed that cancer patients have an elevated cfDNA level (avg. 20ng\/plasma mL); however, its concentration decreased significantly (p=0.02) on average by 50% after treatment compared to the baseline. The same tendency was observed in the case of SAM after XELOX and FOLFOX adjuvant therapy in plasma samples (p=0.03). Moreover, mostly elevated SAM\/SAH ratios were observed in parallel with reduced SAH level after the therapy. Significant (p=0.0001) mean LINE-1 hypomethylation was detected in PBMC (81.84%) compared to cfDNA of plasma (73.76%), furthermore, slightly DNA hypermethylation was noticed in CpG1 position of LINE-1 after chemotherapy in both mononuclear cells and circulating DNA. Lower level of plasma nucleotides was identified in case of adenine, cytosine and uracil after treatment, while thymine and guanine were below the detection limit. The present study demonstrates that the DNA-damaging chemotherapy results in a detectable decrease in cfDNA immediately after the treatment, that was supported by the decrease in the level of the nucleotides measured in the plasma fraction. The methionine cycle is responsible for the DNA methylation maintenance, and though the amount of members of this pathway was reduced, only a moderately increased DNA methylation could be detected even in such a short period time. Co-administration of high dose leucovorin as a folate derivative and a methyl donor with further chemotherapeutic agents may actively contribute to genome alterations.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/57adc6c4-3106-40cc-be5c-5cc7f82809dc\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Colorectal adenocarcinoma,Chemotherapy,Methylation,Plasma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17265"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Zsófia Brigitta Nagy<\/i><\/u><\/presenter>, <presenter><i>Barbara Kinga Barták<\/i><\/presenter>, <presenter><i>Tamás Fodor<\/i><\/presenter>, <presenter><i>Gellért Balázs Karvaly<\/i><\/presenter>, <presenter><i>Sára Zsigrai<\/i><\/presenter>, <presenter><i>Krisztina Andrea Szigeti<\/i><\/presenter>, <presenter><i>Alexandra Kalmár<\/i><\/presenter>, <presenter><i>Magdolna Dank<\/i><\/presenter>, <presenter><i>István Takács<\/i><\/presenter>, <presenter><i>Béla Molnár<\/i><\/presenter>. Semmelweis University, Budapest, Hungary","CSlideId":"","ControlKey":"8b9031b7-ee5e-4c80-999c-7dda90ccabc2","ControlNumber":"4610","DisclosureBlock":"&nbsp;<b>Z. B. Nagy, <\/b> None..<br><b>B. K. Barták, <\/b> None..<br><b>T. Fodor, <\/b> None..<br><b>G. B. Karvaly, <\/b> None..<br><b>S. Zsigrai, <\/b> None..<br><b>K. A. Szigeti, <\/b> None..<br><b>A. Kalmár, <\/b> None..<br><b>M. Dank, <\/b> None..<br><b>I. Takács, <\/b> None..<br><b>B. Molnár, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17265","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/57adc6c4-3106-40cc-be5c-5cc7f82809dc\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"7","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3741","PresenterBiography":null,"PresenterDisplayName":"Zsofia Nagy, PhD","PresenterKey":"962c3ab8-3d48-4547-aba9-c350e7af40fa","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3741. Folic acid combined chemotherapy has an immediate effect on C1 methionine cycle and consequential DNA methylation in liquid biopsy samples of colorectal cancer patients","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Folic acid combined chemotherapy has an immediate effect on C1 methionine cycle and consequential DNA methylation in liquid biopsy samples of colorectal cancer patients","Topics":null,"cSlideId":""},{"Abstract":"<b>Objectives<\/b>: We hypothesize that a validated panel of methylated DNA markers (MDMs) for HPV(+)CSCC will be similar to but distinct from a cohort of HPV(+)OPSCC.<br \/><b>Methods<\/b>: Patients were excluded for recurrent tumor, prior pelvic or head or neck cancer\/neoplasia, chemotherapy &#60; 1 year, prior therapeutic radiation to the target region, prior transplant, insufficient target tissue (&#60;5mm), or if &#60;18 yrs. MDMs identified from sequenced differentially methylated regions were selected from a panel validated for HPV(+)CSCC and evaluated on DNA from independent FFPE HPV(+)OPSCC, HPV(+)CSCC, normal oropharynx tonsil, and normal cervix tissue using methylation-specific PCR. White blood cells (WBCs) were used as a background control.<br \/><b>Results<\/b>: 34 HPV(+)OPSCC, 36 HPV(+)CSCC, 26 normal tonsil tissue, and 24 normal cervical tissue patients met criteria. The HPV(+)OPSCC cohort was older (57 vs 44 yrs, p=0.027), had more frequent alcohol exposure (85% vs 64%, p=0.02), but similar ACE-27 comorbidity scores (p=0.078) and tobacco use (p=0.066). Tumor stages were stage I (47% and 83%), stage II (44% and 11%) and stage III (9% and 6%) for HPV(+)OPSCC and HPV(+)CSCC, respectively. Twenty-one MDMs were evaluated and areas under the receiver operator characteristic curve (AUC) are reported (Table 1). 95% confidence intervals excluded a non-diagnostic null hypothesis AUC of 0.5. 5\/21 (24%) achieved an AUC &#8805; 0.90, 15\/21 (71%) achieved an AUC &#8805; 0.8, and 19\/21 (90%) exhibited better than chance classifications relative to control tonsil tissue (all p&#60;0.001).<br \/><b>Conclusion<\/b>: MDMs have the potential to discriminate both HPV(+)OPSCC and HPV(+)CSCC from their normal tissue controls. 90% of the MDMs discovered for HPV(+)CSCC had better than chance discrimination in HPV(+)OPSCC suggesting a distinct signature between the two subtypes. Future discovery efforts specific to HPV(+)OPSCC is warranted.<br \/><table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{9029BCC1-E1BF-4722-976E-DDF20E7C5744}\"><caption>Methylated DNA Markers in HPV(+)OPSCC and HPV(+)CSCC<\/caption><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><p class=\"Compact\" align=\"center\" style=\"text-align:center\">CSCC<o:p><\/o:p><\/p>  <span style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;; mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">AUC (95% CI)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><p class=\"Compact\" align=\"center\" style=\"text-align:center\">OPSCC<o:p><\/o:p><\/p>  <span style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;; mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">AUC (95% CI)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><p class=\"Compact\" align=\"center\" style=\"text-align:center\">AUC CSCC<o:p><\/o:p><\/p>  <p class=\"Compact\" align=\"center\" style=\"text-align:center\">vs<o:p><\/o:p><\/p>  <p class=\"Compact\" align=\"center\" style=\"text-align:center\">AUC OPSCC<o:p><\/o:p><\/p>  <span style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;; mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">Pvalue<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">GRIN2D<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.72 (0.59-0.85)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.91 (0.83-0.99)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.019<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">EMX1<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.93 (0.86-0.99)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.77 (0.65-0.89)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0191<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">VWC2<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.88 (0.79-0.97)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.57 (0.42-0.72)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0001<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ZNF610<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.99 (0.98-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.89 (0.8-0.97)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0162<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ZNF781.F<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.92 (0.86-0.99)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.79 (0.67-0.91)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0585<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TBX15<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.99 (0.96-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.82 (0.72-0.93)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0025<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TSPYL5<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.94 (0.87-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.82 (0.72-0.93)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.058<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">LOC645323<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.95 (0.89-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.88 (0.8-0.97)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.1952<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ASCL1<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.98 (0.93-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.86 (0.76-0.95)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0187<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ABCB1<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.97 (0.93-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.74 (0.61-0.86)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0001<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ZNF69<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.89 (0.8-0.97)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.95 (0.9-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.2017<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">MAX.chr9<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.97 (0.92-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.82 (0.72-0.93)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0113<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ARHGAP12<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.91 (0.83-0.99)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.9 (0.81-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.9223<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">C1orf114<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.94 (0.86-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.88 (0.8-0.97)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.3366<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">MAX.chr6<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.99 (0.97-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.86 (0.76-0.96)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0099<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">NEUROG3<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.95 (0.89-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.7 (0.57-0.83)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0001<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">NID2<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.98 (0.95-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.86 (0.77-0.95)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0207<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TMEM200C<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.95 (0.89-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.54 (0.39-0.69)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0001<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TTYH1<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.99 (0.98-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.82 (0.71-0.93)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0023<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ZNF773<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.93 (0.86-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.9 (0.82-0.98)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.5696<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">ZNF781.R<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1 (1-1)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.92 (0.86-0.99)<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.0198<\/span><\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/d361daf5-7ae4-4c3d-b002-6dbb2cdbb812\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"DNA methylation,Biomarkers,Head and neck squamous cell carcinoma,Cervical cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17267"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Kathryn M. Van Abel<\/i><\/u><\/presenter>, <presenter><i>David M. Routman<\/i><\/presenter>, <presenter><i>Daniel J. Ma<\/i><\/presenter>, <presenter><i>Karen A. Doering<\/i><\/presenter>, <presenter><i>Kelli N. Burger<\/i><\/presenter>, <presenter><i>Patrick H. Foote<\/i><\/presenter>, <presenter><i>William R. Taylor<\/i><\/presenter>, <presenter><i>Douglas W. Mahoney<\/i><\/presenter>, <presenter><i>Calise K. Berger<\/i><\/presenter>, <presenter><i>Xiaoming Cao<\/i><\/presenter>, <presenter><i>Sara S. Then<\/i><\/presenter>, <presenter><i>Alyssa M. Larish<\/i><\/presenter>, <presenter><i>Eric J. Moore<\/i><\/presenter>, <presenter><i>Joaquin G. Garcia<\/i><\/presenter>, <presenter><i>Rondell P. Graham<\/i><\/presenter>, <presenter><i>Jamie N. Bakkum-Gamez<\/i><\/presenter>, <presenter><i>John B. Kisiel<\/i><\/presenter>. Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN","CSlideId":"","ControlKey":"ccb410a0-e56e-46d4-bad5-8e8f887fccb6","ControlNumber":"2876","DisclosureBlock":"<b>&nbsp;K. M. Van Abel, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Patent, Other Intellectual Property, Yes. <br><b>D. M. Routman, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Patent, Other Intellectual Property, Yes. <br><b>D. J. Ma, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Patent, Other Intellectual Property, Yes. <br><b>K. A. Doering, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Yes. <br><b>K. N. Burger, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Yes. <br><b>P. H. Foote, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Yes. <br><b>W. R. Taylor, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Patent, Other Intellectual Property, Yes. <br><b>D. W. Mahoney, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Patent, Other Intellectual Property, Yes. <br><b>C. K. Berger, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Yes. <br><b>X. Cao, <\/b> <br><b>Exact Sciences<\/b> Stock Option, Patent, No.<br><b>S. S. Then, <\/b> None..<br><b>A. M. Larish, <\/b> None..<br><b>E. J. Moore, <\/b> None..<br><b>J. G. Garcia, <\/b> None..<br><b>R. P. Graham, <\/b> None.&nbsp;<br><b>J. N. Bakkum-Gamez, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Patent, Other Intellectual Property, Yes. <br><b>J. B. Kisiel, <\/b> <br><b>Exact Sciences (Madison, WI)<\/b> Grant\/Contract, Patent, Other Intellectual Property, Yes.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17267","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/d361daf5-7ae4-4c3d-b002-6dbb2cdbb812\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3742","PresenterBiography":null,"PresenterDisplayName":"Kathryn Van Abel","PresenterKey":"aa0cc1be-77e5-4ea9-af05-8a88d42344b4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3742. Comparison of methylated DNA markers between human papillomavirus mediated carcinoma in oropharynx and cervical cancer: A pilot study","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Comparison of methylated DNA markers between human papillomavirus mediated carcinoma in oropharynx and cervical cancer: A pilot study","Topics":null,"cSlideId":""},{"Abstract":"DNA N6-methyladenine (m6A) modification has been found widely presented in the human genome, and genome-wide DNA methylation profiling in cancer may reveal epigenetic signatures with significant clinical outcomes. Whole genome sequencing data from PacBio single-molecule real-time (SMRT) system provides signals for identifying the presence of m6A in human genomic DNA. We identified 343,199 m6A modification sites with an average density of 122 per Mb in the HCC1395 breast cancer cell line, whereas 722,303 m6A modification sites with average density of 257 per Mb were observed in a matched normal HCC1395BL cell line, meaning that the total number and the average density of m6A methylation sites in the cancer cell line were reduced more than 50% than that in normal cell line. Only small fraction of the methylation sites was found to be shared between the two cell lines, indicating that significant de-methylation (loss) and new methylation (gain) events occurred in HCC1395 cancer cells. A broad distribution of m6A methylation sites across autosomal chromosomes was observed, but the density of m6A methylation sites on chromosome X was extremely low for both HCC1395 and HCC1395BL cell lines. In contrast, the m6A densities on chromosome 7 and chromosome 22, particularly on their q-arms, from HCC1395 were substantially higher (hypermethylation) than other autosomal chromosomes, suggesting that copy number variations may be associated with these chromosomal regions. Most of the m6A methylation sites were located in intergenic and intronic regions, whereas only about 2~3% of the m6A methylation sites were situated in exonic regions, and 12% on ncRNAs. Understanding the genome-wide distinction of DNA methylation between cancer and matched normal cell lines makes it possible to ask more targeted questions and further investigate the role of methylation in cancer.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/4adf0269-4898-4e0f-9299-d07cfc42d316\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Breast cancer,DNA methylation,Genomics,Sequencing,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17270"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Chunlin Xiao<\/i><\/u><\/presenter>, <presenter><i>Valerie Schneider<\/i><\/presenter>. NIH, Bethesda, MD","CSlideId":"","ControlKey":"ce87a1ca-5df1-4bf0-a719-ac20001d92a0","ControlNumber":"2502","DisclosureBlock":"&nbsp;<b>C. Xiao, <\/b> None..<br><b>V. Schneider, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17270","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/4adf0269-4898-4e0f-9299-d07cfc42d316\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"9","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3743","PresenterBiography":null,"PresenterDisplayName":"Chunlin Xiao, PhD","PresenterKey":"00eb6c4f-bd82-45c6-b8e9-49b6f71278f2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3743. Genome-wide profiling of DNA N6-methylation from a breast cancer and a matched normal cell lines","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Genome-wide profiling of DNA N6-methylation from a breast cancer and a matched normal cell lines","Topics":null,"cSlideId":""},{"Abstract":"<b>Introduction: <\/b>Limited number of tumor types have been examined for Orthopedia Homeobox (OTP) expression. In pulmonary carcinoids, loss of expression is a strong indicator of poor prognosis. Here, we investigated <i>OTP<\/i> expression in 37 different tumor types, and the association between<i> OTP <\/i>expression and DNA methylation levels in lung neuroendocrine neoplasms.<br \/><b>Methods: <\/b>We analyzed publicly available multi-omics data (whole-exome-, whole-genome-, RNA sequencing, Epic-850K-methylation array) of 58 typical-, 27 atypical carcinoids, 69 large cell neuroendocrine carcinoma and 51 small cell lung cancer patients and TCGA (The Cancer Genome Atlas) data of 33 tumor types. 850K-methylation analysis was cross validated using targeted pyrosequencing on 35 carcinoids.<br \/><b>Results: <\/b>Results showed bimodality of <i>OTP<\/i> expression in carcinoids (OTP<sup>high<\/sup> versus OTP<sup>low<\/sup> group, likelihood-ratio test <i>p<\/i>=1.5x10<sup>-2<\/sup>), with the OTP<sup>high<\/sup> group specific to pulmonary carcinoids while absent from all other cohorts analyzed. Significantly different DNA methylation levels were observed between OTP<sup>high<\/sup> and OTP<sup>low<\/sup> carcinoids in 12\/34 OTP infinium probes (fdr&#60;0.05 &#38; &#946;-value effect size&#62;0.2). Overall, OTP<sup>low<\/sup><sup> <\/sup>carcinoids harbor a high DNA methylation level as compared to OTP<sup>high<\/sup> carcinoids. OTP<sup>low<\/sup> carcinoids showed a significantly worse overall survival (logrank test <i>p<\/i>=0.0052). Gene set enrichment analysis for somatically mutated genes associated with hallmarks of cancer showed robust enrichment of three hallmarks in the OTP<sup>low<\/sup> group, i.e., sustaining proliferative signaling, evading growth suppressor, and genome instability and mutation.<br \/><b>Conclusion: <\/b>High <i>OTP<\/i> expression is a unique feature of pulmonary carcinoids with a favorable prognosis. In poor prognostic patients, <i>OTP<\/i> expression is lost, most likely due to changes in DNA methylation levels.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/b2078c05-790b-488d-8540-601236ad771c\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"Neuroendocrine tumors,Methylation,Lung cancer: non-small cell,Sequencing,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17271"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Laura Moonen<\/i><\/u><\/presenter>, <presenter><i>Lise Mangiante<\/i><\/presenter>, <presenter><i>Daphne J. G. Leunissen<\/i><\/presenter>, <presenter><i>Lisa M. V. Lap<\/i><\/presenter>, <presenter><i>Aurelie Gabriel<\/i><\/presenter>, <presenter><i>Lisa M. Hillen<\/i><\/presenter>, <presenter><i>Guido M. Roemen<\/i><\/presenter>, <presenter><i>Alexander Koch<\/i><\/presenter>, <presenter><i>Manon Van Engeland<\/i><\/presenter>, <presenter><i>Anne-Marie C. Dingemans<\/i><\/presenter>, <presenter><i>Matthieu Foll<\/i><\/presenter>, <presenter><i>Nicolas Alcala<\/i><\/presenter>, <presenter><i>Lynnette Fernandez-Cuesta<\/i><\/presenter>, <presenter><i>Jules L. Derks<\/i><\/presenter>, <presenter><i>Ernst-Jan M. Speel<\/i><\/presenter>. Maastricht University Medical Centre, Maastricht, Netherlands, International Agency for Research on Cancer\/World Health Organisation (IARC\/WHO), Lyon, France, Erasmus MC Cancer Institute, Rotterdam, Netherlands, Maastricht University Medical Centre, Maastricht, Netherlands","CSlideId":"","ControlKey":"0e703e07-db84-4515-84d9-c6dfea206809","ControlNumber":"388","DisclosureBlock":"&nbsp;<b>L. Moonen, <\/b> None..<br><b>L. Mangiante, <\/b> None..<br><b>D. J. G. Leunissen, <\/b> None..<br><b>L. M. V. Lap, <\/b> None..<br><b>A. Gabriel, <\/b> None..<br><b>L. M. Hillen, <\/b> None..<br><b>G. M. Roemen, <\/b> None..<br><b>A. Koch, <\/b> None.&nbsp;<br><b>M. van Engeland, <\/b> <br><b>Epify BV<\/b> Other, co-founder and shareholder, No. <br><b>A. C. Dingemans, <\/b> <br><b>BMS<\/b> Grant\/Contract, Other, No. <br><b>Abbvie<\/b> Grant\/Contract, No. <br><b>Amgen<\/b> Grant\/Contract, Other, No. <br><b>Roche<\/b> Other, No. <br><b>Eli lilly<\/b> Other, No. <br><b>Boehringer<\/b> Other, No. <br><b>Ingelheim<\/b> Other, No. <br><b>Astra Zeneca<\/b> Other, No. <br><b>Novartis<\/b> Other, No. <br><b>MSD<\/b> Other, No. <br><b>Pharmamar<\/b> Other, No.<br><b>M. Foll, <\/b> None..<br><b>N. Alcala, <\/b> None..<br><b>L. Fernandez-Cuesta, <\/b> None..<br><b>J. L. Derks, <\/b> None.&nbsp;<br><b>E. M. Speel, <\/b> <br><b>Amgen<\/b> Other, Personal fees, No. <br><b>Lilly<\/b> Other, Personal fees, No. <br><b>Novartis<\/b> Grant\/Contract, Other, Personal fees, No. <br><b>AstraZeneca<\/b> Grant\/Contract, No. <br><b>Pfizer<\/b> Grant\/Contract, No. <br><b>Novartis<\/b> Grant\/Contract, No. <br><b>Bayer<\/b> Grant\/Contract, No. <br><b>Abbvie<\/b> non-financial support, No. <br><b>Biocartis<\/b> non-financial support, No.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17271","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/b2078c05-790b-488d-8540-601236ad771c\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3744","PresenterBiography":null,"PresenterDisplayName":"Laura Moonen, MS","PresenterKey":"f189fffe-05d3-4180-a7db-61021ac3b67c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3744. Differential Orthopedia Homeobox (OTP) expression in pulmonary carcinoids is associated with changes in DNA methylation","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Differential Orthopedia Homeobox (OTP) expression in pulmonary carcinoids is associated with changes in DNA methylation","Topics":null,"cSlideId":""},{"Abstract":"Reduction of global DNA methylation is a characteristic epigenetic alteration of various cancer types, including colorectal cancer. Abnormality of several factors, such as DNA methyltransferases (DNMT), demethylases, or deviation in methyl-donor (folate and S-adenosylmethionine) availability can contribute to the development of genome-wide hypomethylation. Detection of epigenetic changes as global DNA hypomethylation in cell-free DNA fraction obtained from blood samples can expand the opportunities for the early recognition of colorectal cancer. One of our main goals was the investigation of global DNA methylation patterns in tissue biopsies (n=183) and cell-free DNA fraction of blood samples (n=48) along the colorectal normal-adenoma-carcinoma sequence and in inflammatory bowel disease. Moreover, we aimed to explore possible underlying mechanisms of genome-wide hypomethylation formation in 12 colorectal tumor tissue sections, containing transition zones. Using LINE-1 pyrosequencing, significantly reduced global DNA methylation level was detected in line with cancer progression in tissue specimens (normal: 77.5&#177;1.7%, adenoma: 72.7&#177;4.8%, carcinoma: 69.7&#177;7.6%, p&#8804;0.0001) and in liquid biopsies as well (normal: 82.0&#177;2.0%, adenoma: 80.0&#177;1.7%, carcinoma: 79.8&#177;1.3%, p&#8804;0.01). However, no significant methylation changes were found in inflammatory bowel disease cases. Analyzing microarray data in silico, altered mRNA expression of certain methylation-, and one-carbon metabolism-related genes were detected in tumorous specimens vs. healthy biopsies, from which <i>DNMT1<\/i> was upregulated, and folate receptor 2 (<i>FOLR2<\/i>) was downregulated. <i>DNMT<\/i> and <i>FOLR2<\/i> expression were validated by immunohistochemistry. Furthermore, significantly reduced folic acid and S-adenosylmethionine content were observed in parallel with diminishing 5-methylcytosine levels in adenoma and carcinoma sections compared to normal adjacent to tumor tissue areas by immunolabeling (p&#8804;0.05). Our results suggest that intraindividual monitoring of genome-wide hypomethylation may assist in the recognition of adenoma formation, cancer progression, or remission as well. Moreover, lower global DNA methylation level could be connected to decreased methyl-donor availability with the contribution of reduced <i>FOLR2<\/i> expression.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/70cd6dc5-c0fd-4bb8-bff7-1258a07e55cc\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-02 DNA methylation,,"},{"Key":"Keywords","Value":"DNA methylation,Liquid biopsies,Folate,Colorectal cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17273"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Krisztina Andrea Szigeti<\/i><\/u><\/presenter>, <presenter><i>Alexandra Kalmár<\/i><\/presenter>, <presenter><i>Gábor Valcz<\/i><\/presenter>, <presenter><i>Barbara Kinga Barták<\/i><\/presenter>, <presenter><i>Zsófia Nagy<\/i><\/presenter>, <presenter><i>Sára Zsigrai<\/i><\/presenter>, <presenter><i>Ildikó Felletár<\/i><\/presenter>, <presenter><i>Árpád V Patai<\/i><\/presenter>, <presenter><i>Tamás Micsik<\/i><\/presenter>, <presenter><i>Márton Papp<\/i><\/presenter>, <presenter><i>Eszter Márkus<\/i><\/presenter>, <presenter><i>Zsolt Tulassay<\/i><\/presenter>, <presenter><i>Péter Igaz<\/i><\/presenter>, <presenter><i>István Takács<\/i><\/presenter>, <presenter><i>Béla Molnár<\/i><\/presenter>. Semmelweis University, Budapest, Hungary, University of Veterinary Medicine, Budapest, Hungary, Pest County Flor Ferenc Hospital, Budapest, Hungary","CSlideId":"","ControlKey":"d1d98341-5e9d-4091-82ef-fbf6161a0027","ControlNumber":"3239","DisclosureBlock":"&nbsp;<b>K. A. Szigeti, <\/b> None..<br><b>A. Kalmár, <\/b> None..<br><b>G. Valcz, <\/b> None..<br><b>B. Barták, <\/b> None..<br><b>Z. Nagy, <\/b> None..<br><b>S. Zsigrai, <\/b> None..<br><b>I. Felletár, <\/b> None..<br><b>Á. Patai, <\/b> None..<br><b>T. Micsik, <\/b> None..<br><b>M. Papp, <\/b> None..<br><b>E. Márkus, <\/b> None..<br><b>Z. Tulassay, <\/b> None..<br><b>P. Igaz, <\/b> None..<br><b>I. Takács, <\/b> None..<br><b>B. Molnár, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17273","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/70cd6dc5-c0fd-4bb8-bff7-1258a07e55cc\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"11","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3745","PresenterBiography":null,"PresenterDisplayName":"Krisztina Szigeti, MS","PresenterKey":"29b114db-d868-4b70-ad27-d6cda033c0b2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3745. Global DNA hypomethylation can be linked to decreased methyl-donor content in colorectal cancer progression","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Global DNA hypomethylation can be linked to decreased methyl-donor content in colorectal cancer progression","Topics":null,"cSlideId":""},{"Abstract":"Background: Hepatocellular carcinoma (HCC) is regarded as environmental-related cancer due to involvement of chemical carcinogen and viral components in multistage process. Accumulating studies have shown that obesity and non-alcoholic fatty liver disease, which can lead to HCC, have been linked to modern diets that are high in fat and charcoal-grilled processed meat, however, the exact processes through which diet contributes to hepato-carcinogenesis remain unclear. In the present study, we demonstrated that diethylnitrosamine (DEN), a subgroup of the N-nitroso compounds presents in food additive\/preservative, tobacco smoke, and pharmaceutical products, upregulates the Mucin 13, transmembrane mucin, <i>via<\/i> miR-145 suppression accompanied by hepatocarcinogenesis events.<br \/>Methodology: Western blotting and qPCR were performed to examine the treatment effects of DEN on Mucin 13 and associated effector proteins in hepatocellular carcinoma cell (HepG2, Hep3B, C3A, and SK-HEP-1) lines. Chemically induced (DEN; 200 mg\/kg bw; 2-AAF (150 mg\/kg bw) animal model was used to further investigate the Mucin 13 expression. The serum AST, ALT and ALP activity were measured using kits provided by Span diagnostics. Immunohistochemistry was used to stain tumor tissue sections for Mucin 13 expression, and <i>in situ<\/i> hybridization was performed to detect miR-145 levels. Molecular docking studies were performed using Auto dock 4 package.<br \/>Results: Our study demonstrated that DEN treatment facilitates the DNA adducts formation in liver cancer cell lines as compared to vehicle controls. Moreover, DEN treatment upregulates Mucin 13 and associated effector proteins as analyzed by qPCR and Western blotting. Liver section of DEN+2-AAF-administered group showed vacuolization of hepatocytes in the centrizonal area with variation of nuclear size. Clear nuclear atypia in the adenoma was seen. The serum activities of AST, ALP and ALT in diseased animals correlated with the liver cancer progression. Additionally, Mucin 13 was also upregulated by DEN treatment in liver tissues. Intriguingly, nuclear Mucin 13 staining was very less in normal liver tissues, whereas its levels were significantly increased DEN+2-AAF induced HCC. These observations indicate that nuclear localization of Mucin 13 may contribute to the malignant transformation of hepatocytes during carcinogenesis. This revealed significant downregulation of tumor suppressors miR-145 in tumor tissues as compared to normal control. Molecular modelling analysis revealed that DEN interacts with Mucin 13 and forms a stable complex by offering numerous interactions with the residues of Mucin 13.<br \/>Conclusions: We propose that DEN modulates Mucin 13 and associated effector proteins in hepatocarcinogenesis.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB05-03 Epigenetic changes as molecular markers of cancer,,"},{"Key":"Keywords","Value":"Liver cancer,Oncogene,MicroRNA,DNA damage,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/17285"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Shabnam Malik<\/i><\/u><\/presenter>, <presenter><i>Mohammed Sikander<\/i><\/presenter>, <presenter><i>Parvez Khan<\/i><\/presenter>, <presenter><i>Murali M. Yallapu<\/i><\/presenter>, <presenter><i>Swatantra K. Jain<\/i><\/presenter>, <presenter><i>Deepshikha P. Katare<\/i><\/presenter>, <presenter><i>Subhash C. Chauhan<\/i><\/presenter>, <presenter><i>Meena Jaggi<\/i><\/presenter>. The University of Texas Rio Grande Valley, McAllen, TX, Jamia Millia Islamia, New Delhi, India, Jamia Hamdard University, New Delhi, India, Amity University, Noida, India","CSlideId":"","ControlKey":"72b012c4-71dd-4db4-9b58-d885c3bb8221","ControlNumber":"5449","DisclosureBlock":"&nbsp;<b>S. Malik, <\/b> None..<br><b>M. Sikander, <\/b> None..<br><b>P. Khan, <\/b> None..<br><b>M. M. Yallapu, <\/b> None..<br><b>S. K. Jain, <\/b> None..<br><b>D. P. Katare, <\/b> None..<br><b>S. C. Chauhan, <\/b> None..<br><b>M. Jaggi, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"17285","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"12","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3746","PresenterBiography":null,"PresenterDisplayName":"Shabnam Malik, PhD","PresenterKey":"e78de11e-c2cd-4f23-a3d8-96c146cc029e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3746. Influence of diethylnitrosamine on Mucin 13 expression in hepatocellular carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Influence of diethylnitrosamine on Mucin 13 expression in hepatocellular carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Ribosomal protein S3 (rpS3) is a multifunctional protein working in translation, DNA repair, cancer, apoptosis etc. UV induced DNA damage is repaired by the nucleotide excision repair (NER) pathways; defects in these pathways lead to a genetic instability known as xeroderma pigmentosum (XP) eventually developing skin cancers. We discovered that rpS3 associates with transcription factor IIH (TFIIH) via an interaction with the xeroderma pigmentosum complementation group D (XPD) protein and complements its function in the NER pathway. Here, we showed that XP-D cells overexpressing rpS3 showed markedly increased resistance to UV through XPD and rpS3 interaction thus augmenting the helicase activity of XPD protein. Additionally, the knockdown of rpS3 caused reduced NER efficiency and the subsequent addition of rpS3 restored the helicase activity of the TFIIH complex in cells. We present data suggesting that rpS3 is involved in post-excision processing in NER, assisting TFIIH in expediting the repair process by increasing its turnover rate when DNA is damaged. We also propose that rpS3 is a novel accessory protein of the NER pathway and its recruitment to the repair machinery upon UV damage augments repair efficiency by enhancing XPD helicase function and increasing its turnover rate, thus facilitating DNA repair. In addition to this, manipulations of rpS3 gene could complement XP-D phenotype and prevent UV damage and skin cancer occurrence. Animal studies strongly indicate that these result could be applied not only for the development of cancer drugs but also for cosmeceuticals. [1] FASEB J. (2020) 34: 8102 [2] Cell &#38; Mol Life Sci (2021) 78: 3591","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":"https:\/\/cslide-us.ctimeetingtech.com\/play\/592627a5-44ed-439a-a465-e3ad6884ef67\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png"},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++MCB07-05 Radiation-induced DNA damage,,"},{"Key":"Keywords","Value":"Skin carcinogenesis,Radiation,DNA damage response,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":"https:\/\/cattendee.abstractsonline.com\/meeting\/10517\/Presentation\/19201"},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Joon Kim<\/i><\/u><\/presenter>, <presenter><i>Yong-Joon Park<\/i><\/presenter>, <presenter><i>Tae Sung Kim<\/i><\/presenter>, <presenter><i>Woo Sung Ahn<\/i><\/presenter>, <presenter><i>Hag Dong Kim<\/i><\/presenter>. Korea University, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"b934db68-bb5a-4c02-b956-db9779a8d1ac","ControlNumber":"1420","DisclosureBlock":"&nbsp;<b>J. Kim, <\/b> None..<br><b>Y. Park, <\/b> None..<br><b>T. Kim, <\/b> None..<br><b>W. Ahn, <\/b> None..<br><b>H. Kim, <\/b> None.","End":"4\/13\/2022 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"19201","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"MediaItem","OtherContent":null,"PlayerUrl":"https:\/\/cslide-us.ctimeetingtech.com\/play\/592627a5-44ed-439a-a465-e3ad6884ef67\/@v03B8ZJQ\/pdf?cover=https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-cover.png","PlayerUrlReason":null,"PositionInSession":"13","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"3747","PresenterBiography":null,"PresenterDisplayName":"Joon Kim, PhD","PresenterKey":"4549eee3-2dad-46ce-9229-d352fd2d6c1a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"3747. RPS3 positively regulates nucleotide excision repair with respect to XP-D and skin cancers","SearchResultFooter":"","SearchResultHeader":"Apr 13 2022  9:00AM","SessionId":"421","SessionOnDemand":"False","SessionTitle":"DNA Modification: Mechanism to Biomarkers to Treatment","ShowChatLink":"false","Start":"4\/13\/2022 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"RPS3 positively regulates nucleotide excision repair with respect to XP-D and skin cancers","Topics":null,"cSlideId":""}]